[DAD, new intensive chemotherapy for patients with myeloma: a preliminary report].
A new intensive chemotherapy regimen, DAD, composed of doxorubicin, melphalan and dexamethasone, was given to 17 patients with multiple myeloma. The end point of this regimen was to obtain a deep posttreatment nadir in the M-protein levels so as to increase the chance of plateau attainment which would be associated with prolonged survival in each patient. It was noteworthy that all the 17 evaluable patients achieved a partial response. Nine of the 17 (52.9%) attained a plateau. Ten of the 17 patients (58.8%) obtained a deep posttreatment nadir in their M-protein levels (IgG < 2,000 mg/dl, IgA < 1,000 mg/dl, BJP = 0 g/dl/day), and six of them reached a plateau phase, which was not significantly more frequent than those who did not obtain a deep posttreatment nadir in their M-protein levels (three of seven reached plateau phase). The median survival of the 17 patients (37.6 months) was significantly prolonged compared with that of patients treated with our previous chemotherapy regimens, VMCP (22.5 months) and MMPP (23.5 months), and was comparable to that of MMCP (29.5 months).
Miwa
Hiroshi
H
Department of Internal Medicine, Division of Hematology, Aichi Medical University.
Nagura
Eiichi
E
Shimizu
Kazuyuki
K
Nitta
Masakazu
M
Ichikawa
Atsushi
A
Ohno
Toshihito
T
Kinoshita
Tomohiro
T
Shibata
Toshihiko
T
Sao
Hiroshi
H
Murase
Takuhei
T
Takeyama
Hideo
H
Wakita
Atsushi
A
Saito
Hidehiko
H
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012074:Remission Induction; D016896:Treatment Outcome
D003907:Dexamethasone; D004317:Doxorubicin; D008558:Melphalan